EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC-ND 4.0

Lassa fever vaccine candidates: A scoping review of vaccine clinical trials

Giorgia Sulis iD, Alexandra Peebles, Nicole E Basta iD

Tropical Medicine & International Health · 2023-06 · 28 (6) · 420-431

DOI: 10.1111/tmi.13876 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Tropical Medicine & International Health, online erschienen am 24.04.2023. Verfasst von Giorgia Sulis und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada. Hauptthemen laut MEDLINE: Lassa Fever, Viral Vaccines. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Lassa fever (LF) is caused by a viral pathogen with pandemic potential. LF vaccines have the potential to prevent significant disease in individuals at risk of infection, but no such vaccine has been licensed or authorised for use thus far. We conducted a scoping review to identify and compare registered phase 1, 2 or 3 clinical trials of LF vaccine candidates, and appraise the current trajectory of LF vaccine development.

Method

We systematically searched 24 trial registries, PubMed, relevant conference abstracts and additional grey literature sources up to 27 October 2022. After extracting key details about each vaccine candidate and each eligible trial, we qualitatively synthesised the evidence.

Results

We found that four LF vaccine candidates (INO‐4500, MV‐LASV, rVSV∆G‐LASV‐GPC, and EBS‐LASV) have entered the clinical stage of assessment. Five phase 1 trials (all focused on healthy adults) and one phase 2 trial (involving a broader age group from 18 months to 70 years) evaluating one of these vaccines have been registered to date. Here, we describe the characteristics of each vaccine candidate and trial and compare them to WHO's target product profile for Lassa vaccines.

Conclusion

Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lassa FeverViral VaccinesHumansLassa virus

Stichwörter der Autor:innen

LASVclinical trialpriority pathogensvaccine candidatevaccine developmentviral haemorrhagic fever

Substanzen

Viral Vaccines

Autor:innen und Institutionen

  • School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
  • Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.
  • Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada.

ORCID-Profile: Giorgia Sulis, Nicole E Basta

Förderung

  • NIAID NIH HHS

Zitieren

APA

Sulis, G., Peebles, A., & Basta, N. E. (2023). Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. Tropical Medicine & International Health, 28(6), 420-431. https://doi.org/10.1111/tmi.13876

Vancouver

Sulis G, Peebles A, Basta NE. Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. Tropical Medicine & International Health. 2023;28(6):420-431. doi:10.1111/tmi.13876

BibTeX
@article{Sulis2023,
  author = {Sulis, Giorgia and Peebles, Alexandra and Basta, Nicole E},
  title = {Lassa fever vaccine candidates: A scoping review of vaccine clinical trials},
  journal = {Tropical Medicine & International Health},
  year = {2023},
  volume = {28},
  number = {6},
  pages = {420--431},
  doi = {10.1111/tmi.13876}
}
Kostenlos starten →